Risks and benefits of antiplatelet therapies

Abstract

This article will provide an overview of the key developments and advances seen within the field of antiplatelet therapies over the last decade. For each pharmacological agent currently used in clinical practice, the article will provide some insights into their mechanism of action along with the pros and cons associated with their use. In addition, an overview of the evidence base that underpins and helps to define the place in therapy of the currently available antiplatelet agents will be provided.

Understanding the ECG. Part 9: Myocardial ischaemia and infarction (part B)

“…All patients should be commenced on an aggressive anti-thrombotic regime to inhibit clot formation (Marshall, 2011). A typical protocol includes dual anti-platelet therapy in the form of aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) (Khan, 2015). Loading doses are given if the patient is not already established on these drugs (Overbaugh, 2009).…”